MCT PROTEIN INHIBITOR-RELATED PROGNOSTIC AND THERAPEUTIC METHODS

摘要

This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4- positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.